Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C134 Re-Administration in Recurrent Malignant Glioma
NCT06193174Phase 1Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C134 in malignant glioma, glioblastoma multiforme (GBM), Gliosarcoma (GS) and 1 more, sponsored by University of Alabama at Birmingham. Primary endpoint: Treatment-Emergent Adverse Events at 12 months. Started Jun 2024; status: terminated.
02
Drugs
C134
03
Conditions
malignant gliomaglioblastoma multiforme (GBM)Gliosarcoma (GS)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT06193174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193174.